Budget impact model of acellular tissue engineered vessel for the repair of extremity arterial trauma when autologous vein is not feasible
ATEV was projected to be cost-saving over 3 years for both trauma centers and third-party payers due to reductions in the costs related to amputations and conduit infections.
Authors
- Ravi R. Rajani (ORCID: https://orcid.org/0000-0001-6839-6011)
- Mary Panaccio
- Fulton Velez (ORCID: https://orcid.org/0000-0001-9054-5933)
- Daniel C. Malone (ORCID: https://orcid.org/0000-0002-5006-9394)
- Laura E. Niklason (ORCID: https://orcid.org/0000-0002-5156-504X)
- Kacey Kathleen Carter
- Li Sun (ORCID: https://orcid.org/0000-0002-7845-9706)
- Lisa Bloudek
Institutions
- Emory University (US)
- Humacyte (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-02-18
- DOI
- https://doi.org/10.1080/13696998.2025.2469460
- Citations
- 2
- Primary Topic
- Cardiac, Anesthesia and Surgical Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 2.78